Avanos Medical(AVNS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported full year net sales of $701 million, exceeding the revised guidance range following Q3 [4] - Adjusted diluted earnings per share for the year was $0.94, finishing at the high end of the earnings guidance range [4] - For Q4, net sales were approximately $181 million, with adjusted diluted earnings per share of $0.29 and adjusted EBITDA of $28 million [11] Business Line Data and Key Metrics Changes - Specialty Nutrition Systems portfolio grew over 8% organically compared to the prior year, with strong demand in long-term and short-term enteral feeding products [6][15] - Pain Management & Recovery portfolio saw normalized organic sales up 2.3%, driven by strong performance in the radiofrequency ablation business [8][16] - The Game Ready portfolio experienced a slight decline year-over-year but maintained similar revenue levels throughout 2025 [9][17] Market Data and Key Metrics Changes - The Specialty Nutrition Systems segment's operating profit was 19%, down 100 basis points year-over-year due to tariff impacts [16] - The Pain Management & Recovery segment's operating profit improved to 4%, a 270 basis point increase compared to the previous year [17] - The hyaluronic acid injections and IV therapy product lines reported a decline of over 35% due to the divestiture of the HA business [18] Company Strategy and Development Direction - The company is focused on five strategic imperatives: accelerating organic growth, managing tariff impacts, realizing operating efficiencies, improving or divesting underperforming assets, and acquiring synergistic businesses [10] - The company is executing a China exit strategy, aiming to have all syringe manufacturing operations out of China by June 2026 [12][21] - The integration of Nexus Medical into the neonatal portfolio is progressing well, with expectations for double-digit growth in 2026 [13][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for continued growth in 2026, despite anticipated tariff impacts [19][23] - The company expects net sales in the range of $700 million to $720 million for 2026, with mid to high single-digit growth in the Specialty Nutrition Systems segment [20] - Management highlighted the importance of tariff mitigation strategies and expects gross margin improvements in the second half of 2026 [19][35] Other Important Information - The company generated $43 million of free cash flow for the full year, higher than anticipated [19] - Capital expenditures for 2026 are expected to be around $25 million, slightly lower than 2025 [22] - The annual effective tax rate is anticipated to be about 29% [22] Q&A Session Summary Question: Insights on tariffs and 2026 outlook - Management estimates a $30 million impact from tariffs in 2026, with a significant portion related to China [27][29] - The company is confident in exiting China by June and delivering products from Mexico and Cambodia [28] Question: Revenue guidance and organic growth rates - Organic growth is expected to be around 5% at the consolidated level, with mid to high single digits for Specialty Nutrition Systems and low to mid single digits for Pain Management & Recovery [38] Question: Operating leverage and cost-saving initiatives - Management expressed high confidence in continuing to drive efficiency and cost management in 2026 [39][40] - R&D spending will remain consistent, with a shift towards more external projects [43] Question: Performance of Specialty Nutrition Systems and Nexus - Demand for the Specialty Nutrition Systems portfolio remains high, with Nexus performing better than expected [45][46]